Core Viewpoint - HealthLynked Corp. is committed to long-term growth and enhancing shareholder value through strategic initiatives, including a reverse stock split to strengthen its capital structure and market positioning [1][2][3]. Share Structure and Market Positioning - The company has completed a reverse stock split, reducing the number of outstanding shares, which increases the per-share price without diluting ownership [2][3]. - This non-dilutive step aims to improve visibility and attract institutional investors, particularly those requiring a minimum share price for participation [3]. Growth Initiatives - HealthLynked has launched its AI healthcare guide, ARi, and is building commercial traction through its telemedicine platform and digital services, which are gaining momentum [4]. - The company is in discussions with major insurance carriers to integrate its technology into care management workflows, potentially driving substantial recurring revenue [5]. Intellectual Property and Innovation - HealthLynked is expanding its intellectual property portfolio, focusing on existing patents in healthcare and AI to support future innovation and maintain market leadership [5]. Future Outlook - The reverse stock split is part of a broader strategy to enhance shareholder value, attract institutional support, and scale operations, with a focus on executing a bold vision for the company's technology [5].

Company Announcement - TIAN RUIXIANG Holdings Ltd. will implement a reverse stock split at a ratio of five (5) to one (1), effective September 5, 2025, with shares trading under the same ticker symbol TIRX on the Nasdaq Capital Market [1] - The par value of the Company's Class A and Class B ordinary shares will increase from US$0.025 to US$0.125 per share as part of the reverse stock split [2] - No fractional shares will be issued; any fractional entitlements will be rounded up to the nearest whole share [2] Company Overview - TIAN RUIXIANG Holdings Ltd. is an insurance broker based in Beijing, China, operating through a variable interest entity [3] - The Company distributes a variety of insurance products, categorized into property and casualty insurance, and other types of insurance such as health and life insurance [3]

GREENWICH, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (the “Company”) reported that it expects to implement the previously announced 1-for-5 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share (“Common Stock”), effective as of September 5, 2025, with trading to begin on a split-adjusted basis at market open on the following business day, September 8, 2025. As a result of the reverse stock split, every five shares of Co ...

Group 1: Stock Split Overview - A high-profile electric-vehicle (EV) manufacturer, Lucid Group, has announced a 1-for-10 reverse stock split, consolidating over 3 billion outstanding shares to approximately 307.3 million [6][10] - The reverse stock split will increase Lucid's share price from $1.98 to $19.80 when trading commences [10] - Reverse stock splits are generally viewed negatively by investors, as they often indicate underlying operational struggles [5][7] Group 2: Company Performance and Challenges - Lucid Group's stock has declined nearly 97% since its all-time high in early 2021, reflecting significant operational challenges [11] - The company has consistently lowered its production forecasts, with a 2024 estimate dropping from 90,000 units to just 9,000 [16] - Supply chain issues and delays in launching new models, such as the Gravity SUV, have further hampered Lucid's ability to scale production [17][18] Group 3: Financial Position - Despite operational losses, Lucid Group ended June with over $2.8 billion in cash and investments, supported by Saudi Arabia's Public Investment Fund [19] - The company reported a loss of over $1.5 billion in the first half of 2025 and has accumulated losses of $13.8 billion since inception [19] - There are no immediate solvency issues, but the company has burned through $1.26 billion in cash from operations in just six months [19]

MSP Recovery’s Common Stock Will Begin Trading on Split-Adjusted Basis on Tuesday, September 2, 2025MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. (NASDAQ: MSPR) (the “Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, announces that it will affect a reverse stock split of its Class A common stock at a reverse stock split ratio of 1-for-7, effective at 11:59 P.M. on September 1, 2025, in order to maintain compliance with the minimum $1 ...

Core Points - MSP Recovery, Inc. will implement a reverse stock split of its Class A common stock at a ratio of 1-for-7, effective September 1, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][3] - The reverse stock split has been approved by the Company's stockholders, and the new CUSIP number for the Class A common stock will be 553745-40-7 [2][3] - Following the reverse split, approximately 1.02 million shares of Class A common stock will be issued and outstanding, with trading on a split-adjusted basis commencing on September 2, 2025 [4] Company Overview - MSP Recovery, founded in 2014, specializes in Medicare, Medicaid, commercial, and secondary payer reimbursement recovery, utilizing data-driven solutions to improve the healthcare reimbursement system [5]

Core Viewpoint - SEGG Media Corporation has announced a 1-for-10 reverse stock split aimed at strengthening its foundation for growth and attracting institutional investors, effective August 29, 2025 [1][2]. Group 1: Strategic Objectives - The reverse stock split is part of a deliberate structural strategy to enhance institutional engagement and create long-term value for shareholders [2][3]. - The company aims to achieve three strategic growth objectives through this reverse stock split [3][11]. Group 2: Growth and Acquisitions - The reverse stock split is expected to bolster SEGG Media's capacity for strategic acquisitions, including Veloce Media Group and Nook Holdings, while accelerating operational expansion and revenue growth in the entertainment and gaming sectors [6][7]. - The company has secured commitments of $450 million from United Capital Investments London Limited and Generating Alpha Ltd to support its growth initiatives [5]. Group 3: Market Positioning - The proactive nature of the reverse stock split distinguishes SEGG Media from companies that are forced to undertake such measures to maintain their listings, reflecting a successful turnaround strategy [5]. - The company aims to enhance institutional and algorithmic access by targeting a higher sustained share price, which will attract a broader base of institutional investors and improve trading conditions [11]. Group 4: Market Structure and Manipulation Mitigation - A higher share price range is expected to strengthen market structure by engaging top-tier market makers, leading to improved liquidity and trading volumes [11]. - The reverse stock split and associated CUSIP change are intended to mitigate market manipulation risks, reinforcing the company's measures against short-selling activities [11].

Core Points - Plus Therapeutics, Inc. has confirmed compliance with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities (MVLS) standard of at least $35 million and the stockholders' equity threshold of at least $2.5 million [1][2] - Nasdaq has granted Plus Therapeutics an extension until November 12, 2025, to regain compliance with the $1.00 bid price rule, previously set for September 8, 2025 [2] - The company is under a one-year monitoring period for the Equity Standard, which will last until August 22, 2026, during which it must maintain compliance to avoid delisting [3] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for central nervous system cancers [4] - The company employs advanced technologies combining image-guided local beta radiation and targeted drug delivery, with key programs targeting leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Viewpoint - DarioHealth Corp. is implementing a 20-for-1 reverse stock split of its common stock, effective August 28, 2025, to enhance its stock price and maintain compliance with Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 47,996,572 to about 2,399,829 [2]. - The total number of authorized shares remains unchanged at 400,000,000 [2][5]. - No fractional shares will be issued; any resulting fractions will be rounded up to the nearest whole share [2][3]. Group 2: Approval and Impact - The reverse stock split was approved by the board of directors with stockholder authority at the 2025 Annual Meeting held on July 23, 2025 [3]. - The split will not affect stockholders' percentage ownership or voting power, aside from minor adjustments for fractional shares [3]. Group 3: Adjustments to Securities - All outstanding options, convertible securities, and other equity instruments will be adjusted accordingly to reflect the reverse stock split [4]. Group 4: Company Overview - DarioHealth Corp. is a leader in the digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [6][7]. - The platform provides personalized interventions driven by data analytics for conditions such as diabetes, hypertension, and behavioral health [6][7]. Group 5: Market Position - DarioHealth offers its solutions globally to health plans, self-insured employers, and consumers, aiming to disrupt traditional healthcare approaches [8].

Group 1 - Lucid confirmed a 1-for-10 reverse stock split effective August 29, 2025, to improve its share price and maintain Nasdaq compliance [1] - The reverse split will reduce outstanding shares from approximately 3.07 billion to 307.3 million and authorized shares from 15 billion to 1.5 billion [1] - Trading on a split-adjusted basis will commence on September 2, 2025, under the existing ticker symbol [1] Group 2 - AI price prediction models project Lucid's average share price to be $2.05 by August 29, which translates to an adjusted price of around $20.50 post-split [3][4] - The current stock price is $2.06, indicating a slight decrease of 0.24% in the predicted price [4] - All three AI models show a rare alignment in their predictions, reflecting a lack of bullish catalysts for the stock [8] Group 3 - Lucid's market cap has decreased by over 30% in the past six months, now standing at $6.44 billion [8] - The company faces high execution risk due to weak deliveries, significant cash burn, and intense competition in the EV market [9] - While the reverse stock split may provide temporary relief above the $20 level, analysts warn that the stock could decline again without new catalysts [10]